Target intelligence / Profile preview

MicroRNA 378d-1 (MIR378D1)

Target
MIR378D1
Molecular classification
Other (microRNA, non-coding RNA)
01

Overview

MicroRNA 378d-1 (MIR378D1) is a short, non-coding RNA gene that regulates gene expression by binding to target mRNAs and inhibiting their translation or promoting their degradation. MIR378D1 is transcribed as part of a primary transcript (pri-miRNA) and processed by ribonucleases (Drosha and Dicer) into its mature form, which is incorporated into the RNA-induced silencing complex (RISC). miR-378d-1, as part of the broader miR-378 family, is implicated in key biological processes such as cell proliferation, apoptosis, differentiation, metabolic regulation (notably in adipose and cardiac tissues), and angiogenesis. It has been experimentally linked to various diseases including cancers and cardiovascular conditions, and its expression pattern is being evaluated as a non-invasive biomarker for cancer detection, progression, and prognosis. No direct drug therapies currently target MIR378D1, but experimental strategies for miRNA modulation are under investigation. This information is synthesized based on current genetic, biomedical, and functional data and reflects the current standard understanding of microRNA 378d-1 and its gene MIR378D1.

Other names
hsa-mir-378d-1mir-378d-1MIR378D1
02

Mechanism of action

Not applicable (standard drugs do not directly target this microRNA; experimental strategies may use anti-miRs or miRNA mimics to upregulate or downregulate its activity.)

03

Biological functions

Post-transcriptional gene regulationControl of cell proliferationApoptosisCell differentiationMetabolism and energy regulation in specific tissuesAngiogenesis
04

Disease associations

Cancer (tumor growth, progression, biomarker in several tumors including renal cell carcinoma, esophageal squamous cell carcinoma, liver, colorectal, and lung cancers)Cardiovascular disease (pathogenesis of myocardial infarction, heart failure, coronary heart disease)Other (may play roles in metabolic disease via effects on adipose tissue and brown fat expansion)
05

Safety considerations

Challenges include delivery specificity and off-target effects for any experimental therapy seeking to modulate miRNA functionmiRNAs have pleiotropic and tissue-specific effects, making therapeutic targeting complex and potentially risky
06

Biomarkers

Circulating levels of miR-378 in blood/serum as a biomarker for cancer prognosis (notably, renal cell carcinoma)Potential biomarker for prognosis or diagnosis in cardiovascular disease and metabolic conditions

Beyond the preview

Go deeper on MicroRNA 378d-1 (MIR378D1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 378d-1 (MIR378D1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call